文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

STAR试验:激素治疗神经根病的统计分析计划

STeroids Against Radiculopathy (STAR) trial: a statistical analysis plan.
PubMed 文献 · Trials · 2021-01-22

STAR试验是一项多中心前瞻性随机对照试验,评估经椎间孔硬膜外注射激素(TESI)治疗急性腰椎间盘突出所致坐骨神经痛(病程小于8周)的(成本)效果。本统计分析计划预先规定了三个组间比较的主要结局、最小临床相关差异和分析方法。

要点

  • 三个比较组:TESI加左布比卡因与单纯口服止痛药、TESI加左布比卡因与TESI加生理盐水、TESI加生理盐水与单纯口服止痛药。
  • 共同主要结局为躯体功能(Roland Morris残疾问卷)、疼痛强度(0-10分数字评定量表)和总体感知恢复(7点Likert量表二分为恢复与未恢复)。
  • 最小临床相关组间差异:疼痛强度2分、躯体功能4分、恢复率20%。

核心结论

  • 本统计分析计划详细规定了STAR试验的预定分析,旨在提供TESI治疗急性坐骨神经痛(小于8周)(成本)效果的证据。

研究设计与样本

  • 多中心、随机对照、前瞻性试验(RCT),在腰椎间盘突出所致急性坐骨神经痛(小于8周)患者中进行三组比较。
  • 荷兰国家试验注册号NTR4457(2014年3月6日)。

主要发现

  • 共同主要结局为躯体功能(Roland Morris残疾问卷)、疼痛强度(10分数字评定量表)和总体感知恢复(7点Likert量表,二分为恢复与未恢复)。
  • 次要结局为健康相关生活质量(EQ-5D-5L)、患者满意度(7点Likert量表)和手术率,并收集资源利用数据进行经济学评价。

关键数值与推荐

  • 最小临床相关组间差异:疼痛强度2分(范围0-10)、躯体功能4分(范围0-24)、恢复率差异20%。
  • 分析采用意向性治疗,三个比较均设p小于0.05(双侧)。
  • 效应用最大似然法混合模型估计,每个比较按时间点检验组间均值差或比例差,并估计6个月随访期间总体均值差或比例差。
  • 经济学评价用链式方程多元插补处理缺失数据,用似不相关回归估计成本与效应差异,用自举法估计不确定性。

临床怎么用

  • 该统计分析计划为STAR试验的预定分析提供详细方法学框架,供同类RCT的数据分析设计与报告参考。

局限性

  • 摘要未报告试验结果数据、样本量及功效计算信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transforaminal epidural injections with steroids (TESI) are used increasingly for patients with sciatica. However, their safety, effectiveness, and cost-effectiveness are still a matter of debate. This a priori statistical analysis plan describes the methodology of the analysis for the STAR trial that assesses the (cost-)effectiveness of TESI during the acute stage of sciatica (< 8 weeks). METHODS: The STAR trial is a multicentre, randomized controlled, prospective trial (RCT) investigating the (cost-)effectiveness of TESI by making a three-group comparison among patients with acute sciatica due to a herniated lumbar disc (< 8 weeks): (1) TESI combined with levobupivacaine added to oral pain medication (intervention group 1) versus oral pain medication alone (control group), (2) intervention group 1 versus transforaminal epidural injection with levobupivacaine and saline solution added to oral pain medication (intervention group 2), and (3) intervention group 2 versus control group. Co-primary outcomes were physical functioning (Roland Morris Disability Questionnaire), pain intensity (10-point numerical rating scale), and global perceived recovery (7-point Likert scale, dichotomized into 'recovered' and 'not recovered'). For all three comparisons, we defined the following minimal clinically relevant between-group differences: two points for pain intensity (range 0-10), four points for physical functioning (range 0-24) and a 20% difference in recovery rate. Secondary outcomes are health-related quality of life (EQ-5D-5L) and patient satisfaction (7-point Likert scale) and surgery rate. We also collected resource use data to perform an economic evaluation. Analyses will be conducted by intention-to-treat with p < 0.05 (two-tailed) for all three comparisons. Effects will be estimated using mixed models by maximum likelihood. For each comparison, mean differences, or difference in proportions, between groups will be tested per time point and an overall mean difference, or difference in proportions, between groups during the complete duration of follow-up (6 months) will be estimated. In the economic evaluation, Multivariate Imputation by Chained Equations will be used to handle missing data. Cost and effect differences will be estimated using seemingly unrelated regression, and uncertainty will be estimated using bootstrapping techniques. DISCUSSION: This statistical analysis plan provides detailed information on the intended analysis of the STAR trial, which aims to deliver evidence about the (cost-)effectiveness of TESI during the acute phase of sciatica (< 8 weeks). TRIAL REGISTRATION: Dutch National trial register NTR4457 (6 March 2014).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ter Meulen BC, van Dongen JM, van der Vegt M, et al. STeroids Against Radiculopathy (STAR) trial: a statistical analysis plan. Trials. 2021. PMID: 33482888. doi:10.1186/s13063-020-05018-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。